REG - RUA Life Sciences - Result of AGM

Rua Life SciencesAnnouncement

23/08/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW2528Ka&default-theme=true

RNS Number : 2528K  RUA Life Sciences PLC  23 August 2023

23 August 2023

 

 

RUA Life Sciences plc

 

("RUA" the "Company" or the "Group")

 

Result of AGM

 

RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical
device businesses focussed on the exploitation of the world's leading
long-term implantable biostable polymer (Elast-Eon ™), announces that all
resolutions put forward to its Annual General Meeting held earlier today were
duly passed and the votes cast were as follows:

 

 Res No.  Votes For  %        Votes Against  %       Votes Total  % I.S.C.  Votes Withheld
 1        3,120,357  100.00%  0              0.00%   3,120,357    14.07     0
 2        2,229,757  71.48%   889,792        28.52%  3,119,549    14.06     808
 3        2,955,917  95.24%   147,790        4.76%   3,103,707    13.99     16,650
 4        2,951,476  95.23%   147,790        4.77%   3,099,266    13.97     21,091
 5        3,093,484  99.67%   10,223         0.33%   3,103,707    13.99     16,650
 6        2,980,778  95.53%   139,356        4.47%   3,120,134    14.06     223
 7        2,980,448  95.53%   139,569        4.47%   3,120,017    14.06     340
 8        2,951,597  95.48%   139,569        4.52%   3,091,166    13.93     29,191

 

The full text of each of the resolutions is set out in the notice of Annual
General Meeting, copies of which are available on the Company's website
(www.rualifesciences.com (http://www.rualifesciences.com) ).

QCA Code - statement regarding voting result

The board notes that although Resolution 2 (remuneration committee report)
passed with the requisite majority, it received more than 20% of votes against
the board's recommendation. We thank shareholders for their support and the
Board will look to continue engagement throughout the year. The board
encourages an open and constructive dialogue directly with shareholders and
continue to be willing to engage with any shareholder on any relevant topics
should they so wish.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman
                          Tel: +44 (0)1294 317073

Dr Caroline Stretton, Group MD
             Tel: +44 (0)1294 317073

 

Cenkos Securities plc (Nominated Adviser and Broker)   Tel: +44 (0)20 7397
8900

Giles Balleny / Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPJMATMTBTBAJ